Loading...
Market
What will be Sanofi's tolebrutinib market share among MS treatments by December 31, 2025?
2
Resolution / Starting Odds
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Industry market share reports and Sanofi's financial statements
Story
Sanofi's Tolebrutinib Delays Disability Progression in MS by 31% in Phase 3 Trial
Sep 20, 2024, 09:55 AM
Sanofi has announced that its experimental drug, tolebrutinib, has demonstrated a significant 31% delay in the progression of disability for patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in a phase 3 trial. This development provides hope for patients suffering from this progressive form of multiple sclerosis, for which there is currently no effective treatment. The French pharmaceutical company plans to file for approval of tolebrutinib later this year. Despite the promising results, the drug showed higher new Gd-enhancing T1 lesions compared to teriflunomide in the GEMINI-1/2 trials. The results were presented at the ECTRIMS 2024 conference.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Yes • 50%
No • 50%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%